Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky

T. Rusman, R. F. van Vollenhoven, I. E. van der Horst-Bruinsma

Current Rheumatology Reports · 2018 · Review

doi:10.1007/s11926-018-0744-2

Abstract

Purpose of Review. Ankylosing spondylitis (AS) was historically seen as a predominantly male disease. However, more recent data showed a more homogenous sex prevalence. Unfortunately, in many studies in axial spondyloarthritis (axSpA), the number of women included is low and the analyses are often not stratified for gender distribution. The purpose of this review is to aggregate the existing data on gender differences in axSpA in order to increase the awareness that female axSpA patients are still under-recognized.

Recent Findings. Several studies considering gender differences revealed that female axSpA patients had different disease manifestations due to different immunological, hormonal, and genetic responses. For instance, allelic frequencies of the AHNK-gene and tissue non-specific alkaline phosphatase (TNAP) haplotypes differed between men and women with ankylosing spondylitis (AS). In addition, different levels of tumor necrosis factor (TNF), interleukins IL-6, IL-17, and IL-18, were found between the two sexes. Furthermore, female patients show a higher diagnostic delay compared to males. Several studies indicate a higher frequency of extra-articular manifestations (EAM) in female axSpA patients, such as enthesitis, psoriasis, and inflammatory bowel disease (IBD), whereas acute anterior uveitis is more prevalent in male patients. Male AS patients more frequently show a higher Bath Ankylosing Spondylitis Radiology Index (BASRI) scores and modified Stoke Ankylosing Spondylitis Spine Scores (mSASSS) than females, which indicates that males have higher radiological damage and radiographic progression. However, disease activity (BASDAI) and quality of life (AsQol) scores are significantly higher in women, and more importantly, they have significantly lower response rates to treatment with TNF inhibitors (TNFi) and a significantly lower drug adherence.

Summary. Despite the fact that men with axial SpA have a worse radiologic prognosis, women have a high disease burden, in part because they have a longer delay in diagnosis, higher disease activity, and significantly less responsiveness to treatment with TNFi.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

There is increasing evidence that in drug development, any potential sex and gender differences in general have not been addressed sufficiently, and sometimes never addressed at all [••, ]. For example, in vitro experiments are performed in cell lines with unknown XX/XY karyotype, animal experiments are only performed in male mice (in order to prevent “hormonal disturbances”), women are underrepresented in phase 1 and 2 trials (despite significant differences in pharmacodynamics and pharmacokinetics between men and women), phase 3 trials are not powered to detect gender differences in efficacy or toxicity, and post-marketing studies are not always analyzed after stratification for sex [••, ]. Recently, sex and gender differences in several diseases are being recognized, such as clinical presentation of cardiovascular disease.

First, the terms sex and gender, which are often used interchangeably, need clarification. The term “sex differences” is used to describe differences in biological processes between males and females, such as hormonal, genetic, and immunological functions in a disease. The term gender can be used for describing a person’s self-perception as male or female, and behavioral expression (such as coping style and disease perception). Thus, besides cardiovascular diseases, gender differences in disease manifestations have also been described in rheumatic diseases, including spondyloarthritis (SpA).

SpA is a chronic inflammatory rheumatic disease that can be divided into predominantly axial and predominantly peripheral forms. Axial SpA (axSpA) encompasses ankylosing spondylitis (AS) with radiological signs of sacroiliitis, and a type without radiographic sacroiliitis, initially called “spondylitic disease without radiographic sacroiliitis” and now renamed “non-radiographic axial SpA” or nr-axSpA. Nr-axSpA might progress to AS within several years. Historically, the male-female prevalence ratio showed a large overestimation favoring males, especially among AS patients; for example, initial studies showed a male-female ratio of 10:1. Subsequently, this ratio has been reported to be approximately 3:1. The most current study reports a steady decline in the male-female ratio among patients with AS/axSpA in Switzerland from 2.57:1 in 1980, down to 1.03:1 by the end of 2016. In contrast to AS, nr-axSpA patients show hardly any difference in its prevalence among males and females.

Characteristic symptoms of SpA are inflammatory back pain and progressive functional limitations. In addition, extra-articular manifestations (EAM’s) can develop, such as anterior uveitis (30–40%), psoriasis (10%), and inflammatory bowel disease (IBD, 5–10%). Since the introduction of TNF alpha inhibitors (TNFi), the treatment of axSpA has improved dramatically. Although the large benefits of this treatment for many axSpA patients, currently, several studies show gender and sex differences in treatment response and adherence and in several other aspects of axSpA, such as disease manifestations and disease burden [, ••, –].

Despite accumulating study results considering gender and sex differences in axSpA, female patients are still underrepresented in clinical research [••]. This under-recognition results in delay in diagnosis, which causes under-diagnosis and delay of optimal treatment strategies, which leads to increased disease burden in female axSpA patients.

The aim of this review is to aggregate the existing data on gender and sex differences in axSpA, in order to increase the awareness of female axial SpA patients, since there is still under-recognition.

Immunology and Genetics

Immunological and genetic data showed clear sex dimorphisms in response and expression (Table 1). Recent publications revealed a sex difference in immune response of the cytokine TNFα and the interleukin Il-17A. Male axSpA patients showed significant elevated levels of TNFα and Il-17A compared to female patients [•]. In addition, in AS patients with syndesmophytes, men had significantly higher IL-18 levels, whereas women showed significantly elevated IL-6. Moreover, sex differences were also found in gene expression in AS patients. One study identified a sex-specific gene expression profile, showing 291 genes uniquely expressed in female AS patients, 1522 genes expressed in males with AS, and 650 genes expressed in both male and female AS patients compared with healthy matched controls [•]. Another study revealed that different loci of the ANKH gene were associated with AS in male versus female patient. The ANKH gene encodes a progressive ankylosing protein, which is involved in the structural damage in axSpA patients. Moreover, sex differences were found in TNAP (tissue-nonspecific alkaline phosphatase) haplotype, which interplay with the ANKH gene in ossification. This specific TNAP haplotype was associated with AS in men, but not with women with AS.

In addition, sex hormones might also play a role. Estrogen has an anti-inflammatory effect on SpA manifestations by inhibiting TNF alpha production, although contradicting results were presented. One older study revealed a decrease in arthritis and clinical activity in 17 female AS patients after oral estrogen therapy. They also demonstrated that in premenopausal female patients with active AS, the estrogen levels were lower compared to females with inactive disease and significantly lower compared to controls. Also, in postmenopausal AS patients, estrogen levels were lower compared to controls. However, a more recent study showed neither difference in onset nor severity in 571 female AS patients, of which 448 women had used oral estrogen therapy and 123 did not. In a study with a mouse model, the female mice with high estrogen levels had significantly less severe arthritis and SpA manifestations (such as spondylitis, enthesitis, and bowel inflammation) compared to mice with low estrogen levels. In a review and case-control study of 50 males and 10 female AS patients, Giltay et al. described that serum testosterone levels were not elevated in AS patients compared to controls and did not seem to influence progression of AS. However, the precursor of both testosterone and estradiol, dehydroepiandrosterone (DHEAS), which enhances the Th1 immune response, might play a role in the onset and severity of the AS (Table 1). Furthermore, the review revealed that the role of sex steroids in the pathogenesis of AS needs further investigation.

These results considering sex differences in immune response, genetic associations and sex hormones, show biological mechanisms, which might contribute to different disease manifestations, disease perception, and treatment response in men and women with axSpA.

Delay in Diagnosis

The age of onset of AS does not differ between males and females, but female seem to have a relatively longer delay in diagnosis (Table 2). For example, this delay in 1976 was reported to be approximately 10 years in female versus 3 years in male patients. Later observations showed a median delay of 9 to 14 years in female and 5 to 7 in male patients. A recent meta-analysis covering a total of 42 studies including 23,889 patients (32.3% women) showed a significantly longer delay in diagnosis among female patients compared to males, 8.8 versus 6.5 years, respectively, with a significant overall effect of all included studies of approximately 0.6 years (p < 0.0001; 95%CI 0.31–0.89) [•]. Only one study revealed a higher diagnostic delay in males compared to females, 9.9 and 6.3 years, respectively. Incidentally, among AS patients as a whole, the median delay in diagnosis is significantly longer in HLA-B27-negative patients (11.4 years) than among those who possess this gene (8.5 years).

Several reasons have been described to explain the longer diagnostic delay among females, such as the known differences in the presenting clinical symptoms reported by female patients, such as a lower frequency of typical inflammatory back pain as one of the presenting manifestation, more prominent upper thoracic and neck or wide spread pain, along with less severe or slower progression of radiographic damage. Female patients who report wide spread pain are twice as likely to have a delayed diagnosis compared to those without this symptom. The group with wide spread pain was frequently misdiagnosed with fibromyalgia, since it has some overlapping symptoms with axSpA. Almost 25% of female axSpA patients were misdiagnosed at first, although both male and female patients had nonspecific low back pain as pre-SpA diagnosis. This could be the result of physicians’ bias that axSpA is mostly a male disease, and their lack of knowledge of the different disease manifestation in female patients.

In conclusion, despite the improvement in delay of diagnosis in women with axSpA, there is still a longer delay and more often misdiagnosis in women, which increase the disease burden in the female patient group.

Extra-Articular Manifestations

Female gender was found to be positively associated with several extra-articular manifestations (EAM) (Table 3), but others found no differences. Conflicting results have also been reported regarding gender differences in occurrence of acute anterior uveitis (AAU), the most common EAM. It seems to occur more commonly among male patients [•,, ], but a systematic literature review reported occurrence of AAU to be 28.5% in males versus 33.3% among females. However, this study made no distinction between different types of uveitis, which is important because intermediate and posterior uveitis are unusual in SpA, and more often associated with other diseases, such as sarcoidosis.

Enthesitis is more common and more severe among in female patients. This finding could be an explanation for the same or even higher disease burden in female patients compared to males, despite their slower radiological progression. Three studies, including a systematic review and meta-analysis, indicate that female patients experience more inflammatory bowel disease (IBD) compared to male patients. In addition, there are some studies that showed a higher prevalence of psoriasis in female axSpA patients compared to males.

Overall, although there are some conflicting results, it seems that female patients more frequently have enthesitis and IBD, whereas male patients may have AAU more frequently.

Disease Activity Scores

Female axSpA patients showed a higher disease burden concerning disease activity and pain scores (Table 4). Reported were significantly higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores in females compared to males, of which the items fatigue, total back pain, and longer duration of morning stiffness showed the largest differences [••,,, •,,,,,, ]. Only one study showed higher Bath Ankylosing Spondylitis Functionality (BASFI) scores in female patients, whereas the other studies showed no gender difference. The limited data available considering the AS Disease Activity Score (ASDAS) showed no gender differences [••, •]. Studies on sex differences in CRP levels showed significantly higher baseline levels in male patients compared to females [••, •,,, ]. Data on ESR levels were inconclusive to identify sex differences.

Quality of Life

Female gender corresponded with a significantly lower quality of life (QoL) according to the ASQoL (questionnaire for QoL in AS) compared to male patients in most studies [•,,, ] (Table 4). However, other QoL questionnaires, such as EuroQL and SF-36 scores, showed no (large) differences over time [•]. Female axSpA patients also showed higher Bath Ankylosing Spondylitis Global scores (BASG), which indicate that female patients experienced worse overall well-being in daily life compared to males. These results are consistent with observations done in rheumatoid arthritis and other autoimmune diseases, where female patients have worse QoL scores compared with males despite equal control of inflammation.

Differences in Radiological Progression

Overall, most studies were small but showed that men had worse radiological progression compared to women, although one study showed the opposite (Table 5). Frequently, male sex was indicated as a prognostic factor for worse and more severe radiological progression including development of syndesmophytes, measured with the BASRI-spine and mSASSS scores. Additionally, hip involvement seems to be worse in male patients. However, more extensively research revealed a small nuance in radiological progression. Female patients seem to have higher progression in the cervical spine and males in the lumbar spine, thereby female patients showed slow radiological progression and males fast progression. This slower radiological progression in women probably results in more nr-axSpA diagnoses in female axSpA patients compared to males. Despite the lower radiological progression, the disease burden in female patients is still high. Several studies confirmed that nr-axSpA patients (both male and female) showed the same levels of disease activity, pain, and impaired function as “radiological axSpA” or AS patients.

Treatment Response and Drug Adherence

Overall, treatment efficacy of TNFi is significantly lower in women compared to men with axSpA, and they have a significantly lower drug adherence (Table 6). In most randomized controlled trials, these gender differences in efficacy were not shown due to the relatively low numbers of women included and because most studies were only powered for efficacy of the drug and not to detect gender differences in response. However, if the data of these trials were reanalyzed after stratification for gender, a significantly lower level of response (ASDAS and BASDAI) and treatment adherence in females was found [, ••,,, –,, ] (Table 6). These studies indicate that women with AS have doubled risk at lower drug adherence of TNFi compared with males. In addition, significantly more female patients switched TNFi treatment, which indicate worse treatment adherence in female patients. This may also imply a weaker treatment response.

Some predictors were associated with a better treatment response, such as the presence of the HLA-B27, absence of enthesitis, short disease duration, and being TNFi naive. Interestingly, these predictors were negatively associated with female gender, because women with AS have a higher prevalence of enthesitis and had a longer delay in diagnosis (Tables 2 and 3). These factors may contribute to the gender differences in TNFi adherence and response.

Currently, gender differences in treatment response are still a dilemma. However, almost no specific studies considering gender and sex differences were performed. A re-analysis of randomized clinical trials, which are powered for efficacy and toxicity between the studied drug (or placebo), and not for sex differences, has only been done in three TNFi studies with etanercept, adalimumab, and infliximab, but not for all the other TNFi nor for the interleukin 17 blocker secukinumab.

Recently, several hypotheses for gender and sex differences in response to TNFi were formulated, such as difference in body composition. Females have, in general, higher fat percentages compared to males, and different gonadal hormones and even different gene expressions compared to male axSpA patients [••].

Several studies showed that a higher body mass index (BMI) resulted in a lower TNFi treatment response [, •], of which one of the studies even found a correlation between BMI and the inflammation marker CRP in female axSpA patients [•]. In addition, other data revealed that there was a significant relationship between female AS patients with high disease activity scores (ASDAS and BASDAI) and a high body fat percentage (BF%) or fat mass index (FMI), as contradicting male patients with high disease activity scores had low BF% and FMI. Overall, women in general have a higher BF% compared to males, which might be an explanation for the worse TNFi treatment response in female axSpA patients [••]. As mentioned previously, male axSpA patients showed a significantly elevated level of TNFα compared to female patients, which might be another possible explanation for a worse TNFi treatment response in female axSpA patients.

Conclusion

Despite the fact that male axSpA patients has more radiographic damage compared to females, female patients have a higher disease burden due to a longer diagnostic delay, higher disease activity, and a lower efficacy of treatment. Although there is increased recognition, of sex and gender differences in axSpA, this review also demonstrated a persistent lack of comprehensive knowledge about disease manifestations in female patients. Further studies into sex and gender differences in the manifestation of axSpA may result in less under-diagnosis and misdiagnosis, more optimal treatment strategies, and decreased overall disease burden in female axSpA patients.

References 92

  1. 1.

    Tannenbaum C, Day D, Matera A. Age and sex in drug development and testing for adults. Pharmacol Res. 2017;121:83-93.

    Not in our library10.1016/j.phrs.2017.04.027

  2. 2.

    Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737-744.

    Not in our library10.1038/nri2394

  3. 3.

    Kouvari M, Yannakoulia M, Souliotis K, Panagiotakos DB. Challenges in sex- and gender-centered prevention and management of cardiovascular disease: implications of genetic, metabolic, and environmental paths. Angiology. 2018;3319718756732.

    Not in our library10.1177/0003319718756732

  4. 4.

    Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine. Handb Exp Pharmacol. 2012;214:3-22.

    Not in our library10.1007/978-3-642-30726-3_1

  5. 5.

    Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.

    Not in our library10.1136/ard.2009.108233

  6. 6.

    Khan MA, van der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. Arthritis Rheum. 1985;28(1):40-43.

    Not in our library10.1002/art.1780280107

  7. 7.

    Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31.

    Not in our library10.1136/ard.2010.133645

  8. 8.

    Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-3418.

    Not in our library10.1002/art.24024

  9. 9.

    Gong Y, Zheng N, Chen SB, Xiao ZY, Wu MY, Liu Y, Zeng QY. Ten years’ experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum. 2012;64(5):1399-1406.

    Not in our library10.1002/art.33453

  10. 10.

    West HF. Aetiology of ankylosing spondylitis. Ann Rheum Dis. 1949;8(2):143-148.

    Not in our library10.1136/ard.8.2.143

  11. 11.

    Polley HF, Slocumb CH. Rheumatoid spondylitis; a study of 1,035 cases. Ann Rheum Dis. 1947;6(2):95-98.

    Not in our library

  12. 12.

    Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53(5):343-364.

    Not in our library10.1097/00005792-197409000-00002

  13. 13.

    Hill HF, Hill AG, Bodmer JG. Clinical diagnosis of ankylosing spondylitis in women and relation to presence of HLA-B27. Ann Rheum Dis. 1976;35(3):267-270.

    Not in our library10.1136/ard.35.3.267

  14. 14.

    Carbone LD, Cooper C, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? Arthritis Rheum. 1992;35(12):1476-1482.

    Not in our library10.1002/art.1780351211

  15. 15.

    Gran JT, Ostensen M, Husby G. A clinical comparison between males and females with ankylosing spondylitis. J Rheumatol. 1985;12(1):126-129.

    Not in our library

  16. 16.

    Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol. 1993;20(11):1900-1904.

    Not in our library

  17. 17.

    Masi AT, Wilkins WR. Does male:female sex ratio in ankylosing spondylitis change with age? J Rheumatol. 1996;23(5):947-948.

    Not in our library

  18. 18.

    Calin A, Elswood J, Rigg S, Skevington SM. Ankylosing spondylitis—an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol. 1988;15(8):1234-1238.

    Not in our library

  19. 19.

    Will R, Edmunds L, Elswood J, Calin A. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol. 1990;17(12):1649-1652.

    Not in our library

  20. 20.

    Baumberger H, Khan M. Gradual progressive change to equal prevalence of ankylosing spondylitis among males and females in Switzerland: data from the swiss ankylosing spondylitis society (SVMB) [abstract]. Ann Rheum Dis. 2017.

    Not in our library

  21. 21.

    van den Berg R, van Gaalen F, van der Helm-van Mil A, Huizinga T, van der Heijde D. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Ann Rheum Dis. 2012;71(8):1366-1369.

    Not in our library10.1136/annrheumdis-2011-201081

  22. 22.

    Sieper J, van der Heijde D. Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543-551.

    Not in our library10.1002/art.37803

  23. 23.

    Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford). 2014;53(5):875-881.

    Not in our library10.1093/rheumatology/ket433

  24. 24.
    Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis · 2016
    No notice
  25. 25.

    Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewe R, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396.

    Not in our library10.1136/rmdopen-2016-000396

  26. 26.

    van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis. 2013;72(7):1221-1224.

    Not in our library10.1136/annrheumdis-2012-202431

  27. 27.

    Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69(11):2002-2008.

    Not in our library10.1136/ard.2009.124446

  28. 28.
    Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study · 2011
    No notice
  29. 29.

    Ibanez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT, et al. Muscle wasting in male TNF-alpha blocker naive ankylosing spondylitis patients: a comparison of gender differences in body composition. Rheumatology (Oxford). 2017;56(9):1566-1572.

    Not in our library10.1093/rheumatology/kex187

  30. 30.

    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken). 2010;62(10):1362-1369.

    Not in our library10.1002/acr.20258

  31. 31.

    Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015;16:166.

    Not in our library10.1186/s12891-015-0620-4

  32. 32.

    Paccou J, Bacle-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol. 2012;39(7):1418-1423.

    Not in our library10.3899/jrheum.111337

  33. 33.

    Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958-963.

    Not in our library

  34. 34.

    Gracey E, Yao Y, Green B, Qaiyum Z, Baglaenko Y, Lin A, Anton A, Ayearst R, Yip P, Inman RD. Sexual dimorphism in the Th17 signature of ankylosing spondylitis. Arthritis Rheumatol. 2016;68(3):679-689.

    Not in our library10.1002/art.39464

  35. 35.

    Huang WN, Tso TK, Kuo YC, Tsay GJ. Distinct impacts of syndesmophyte formation on male and female patients with ankylosing spondylitis. Int J Rheum Dis. 2012;15(2):163-168.

    Not in our library10.1111/j.1756-185x.2011.01687.x

  36. 36.

    Tsui HW, Inman RD, Reveille JD, Tsui FW. Association of a TNAP haplotype with ankylosing spondylitis. Arthritis Rheum. 2007;56(1):234-243.

    Not in our library10.1002/art.22307

  37. 37.

    Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther. 2005;7(3):R513-R525.

    Not in our library10.1186/ar1701

  38. 38.

    Jeong H, Bae EK, Kim H, Eun YH, Kim IY, Kim H, Lee J, Jeon CH, Koh EM, Cha HS. Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model. Arthritis Res Ther. 2017;19(1):198.

    Not in our library10.1186/s13075-017-1407-9

  39. 39.

    Mahendira D, Thavaneswaran A, Carty A, Haroon N, Anton A, Passalent L, Alnaqbi KA, Savage L, Aslanyan E, Inman RD. Analysis of the effect of the oral contraceptive pill on clinical outcomes in women with ankylosing spondylitis. J Rheumatol. 2014;41(7):1344-1348.

    Not in our library10.3899/jrheum.130996

  40. 40.

    Aydin T, Karacan I, Demir SE, Sahin Z. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels. Clin Endocrinol. 2005;63(4):467-469.

    Not in our library10.1111/j.1365-2265.2005.02369.x

  41. 41.

    Giltay EJ, Popp-Snijders C, van Schaardenburg D, Dekker-Saeys BJ, Gooren LJ, Dijkmans BA. Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J Rheumatol. 1998;25(12):2389-2394.

    Not in our library

  42. 42.

    Jimenez-Balderas FJ, Tapia-Serrano R, Madero-Cervera JI, Murrieta S, Mintz G. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990;17(4):497-502.

    Not in our library

  43. 43.

    Giltay EJ, van Schaardenburg D, Gooren LJ, Popp-Snijders C, Dijkmans BA. Androgens and ankylosing spondylitis: a role in the pathogenesis? Ann N Y Acad Sci. 1999;876:340-364.

    Not in our library10.1111/j.1749-6632.1999.tb07658.x

  44. 44.

    Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol. 2000;12(4):239-247.

    Not in our library10.1097/00002281-200007000-00002

  45. 45.

    Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61-66.

    Not in our library10.1007/s00296-002-0237-4

  46. 46.

    Mogard E, Lindqvist E, Bergman S, Bremander A. Spinal mobility in axial spondyloarthritis: a cross-sectional clinical study. Musculoskeletal Care. 2017;15(1):36-48.

    Not in our library10.1002/msc.1138

  47. 47.

    Bandinelli F, Salvadorini G, Delle Sedie A, Riente L, Bombardieri S, Matucci-Cerinic M. Impact of gender, work, and clinical presentation on diagnostic delay in Italian patients with primary ankylosing spondylitis. Clin Rheumatol. 2016;35(2):473-478.

    Not in our library10.1007/s10067-015-3005-z

  48. 48.

    Webers C, Essers I, Ramiro S, Stolwijk C, Landewe R, van der Heijde D, et al. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology (Oxford). 2016;55(3):419-428.

    Not in our library10.1093/rheumatology/kev340

  49. 49.

    Landi M, Maldonado-Ficco H, Perez-Alamino R, Maldonado-Cocco JA, Citera G, Arturi P, Sampaio-Barros PD, Flores Alvarado DE, Burgos-Vargas R, Santos E, Palleiro D, Gutiérrez MA, Vieira-Sousa E, Pimentel-Santos F, Paira SO, Berman A, Barrezueta CV, Vazquez-Mellado J, Collantes-Estevez E, RESPONDIA Group. Fundación Reumatológica Argentina Dr. Osvaldo García Morteo. Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (Baltimore). 2016;95(51):e5652.

    Not in our library10.1097/md.0000000000005652

  50. 50.

    Shahlaee A, Mahmoudi M, Nicknam MH, Farhadi E, Fallahi S, Jamshidi AR. Gender differences in Iranian patients with ankylosing spondylitis. Clin Rheumatol. 2015;34(2):285-293.

    Not in our library10.1007/s10067-013-2439-4

  51. 51.

    Bodur H, Ataman S, Bugdayci DS, Rezvani A, Nas K, Uzunca K, et al. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. Rheumatol Int. 2012;32(1):169-176.

    Not in our library10.1007/s00296-010-1599-7

  52. 52.

    Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N. Gender and disease features in Moroccan patients with ankylosing spondylitis. Clin Rheumatol. 2012;31(2):293-297.

    Not in our library10.1007/s10067-011-1819-x

  53. 53.

    Slobodin G, Reyhan I, Avshovich N, Balbir-Gurman A, Boulman N, Elias M, Feld J, Mader R, Markovitz D, Rimar D, Rosner I, Rozenbaum M, Zisman D, Odeh M. Recently diagnosed axial spondyloarthritis: gender differences and factors related to delay in diagnosis. Clin Rheumatol. 2011;30(8):1075-1080.

    Not in our library10.1007/s10067-011-1719-0

  54. 54.

    Roussou E, Sultana S. Spondyloarthritis in women: differences in disease onset, clinical presentation, and bath ankylosing spondylitis disease activity and functional indices (BASDAI and BASFI) between men and women with spondyloarthritides. Clin Rheumatol. 2011;30(1):121-127.

    Not in our library10.1007/s10067-010-1581-5

  55. 55.

    Atagunduz P, Aydin SZ, Bahadir C, Erer B, Direskeneli H. Determinants of early radiographic progression in ankylosing spondylitis. J Rheumatol. 2010;37(11):2356-2361.

    Not in our library10.3899/jrheum.100094

  56. 56.

    Dincer U, Cakar E, Kiralp MZ, Dursun H. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol. 2008;27(4):457-462.

    Not in our library10.1007/s10067-007-0727-6

  57. 57.

    Reed MD, Dharmage S, Boers A, Martin BJ, Buchanan RR, Schachna L. Ankylosing spondylitis: an Australian experience. Intern Med J. 2008;38(5):321-327.

    Not in our library10.1111/j.1445-5994.2007.01471.x

  58. 58.

    Jovani V, Blasco-Blasco M, Ruiz-Cantero MT, Pascual E. Understanding how the diagnostic delay of spondyloarthritis differs between women and men: a systematic review and metaanalysis. J Rheumatol. 2017;44(2):174-183.

    Not in our library10.3899/jrheum.160825

  59. 59.

    Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int. 2007;27(9):865-868.

    Not in our library10.1007/s00296-007-0344-3

  60. 60.

    Zarco P, Gonzalez CM, Rodriguez de la Serna A, Peiro E, Mateo I, Linares L, et al. Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. Reumatol Clin. 2015;11(2):83-89.

    Not in our library10.1016/j.reuma.2014.04.003

  61. 61.

    Tournadre A, Pereira B, Lhoste A, Dubost JJ, Ristori JM, Claudepierre P, Dougados M, Soubrier M. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken). 2013;65(9):1482-1489.

    Not in our library10.1002/acr.22001

  62. 62.

    Ibanez Vodnizza SE, Nurmohamed MT, Visman IM, van Denderen JC, Lems WF, Jaime F, et al. Fat mass lowers the response to tumor necrosis factor-alpha blockers in patients with ankylosing spondylitis. J Rheumatol. 2017;44(9):1355-1361.

    Not in our library10.3899/jrheum.170094

  63. 63.

    Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, et al. The sex influence on response to tumor necrosis factor-alpha inhibitors and remission in axial spondyloarthritis. J Rheumatol. 2017; 10.3899/jrheum.17666.

    Not in our library10.3899/jrheum.17666

  64. 64.

    Kilic G, Kilic E, Ozgocmen S. Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis? Int J Rheum Dis. 2017;20(9):1201-1211.

    Not in our library10.1111/1756-185x.12885

  65. 65.

    Mitulescu TC, Popescu C, Naie A, Predeteanu D, Popescu V, Alexandrescu C, et al. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis. J Med Life. 2015;8(3):319-325.

    Not in our library

  66. 66.

    de Carvalho HM, Bortoluzzo AB, Goncalves CR, da Silva JA, Ximenes AC, Bertolo MB, et al. Gender characterization in a large series of Brazilian patients with spondyloarthritis. Clin Rheumatol. 2012;31(4):687-695.

    Not in our library10.1007/s10067-011-1890-3

  67. 67.

    Braakenburg AM, de Valk HW, de Boer J, Rothova A. Human leukocyte antigen-B27-associated uveitis: long-term follow-up and gender differences. Am J Ophthalmol. 2008;145(3):472-479.

    Not in our library10.1016/j.ajo.2007.11.009

  68. 68.

    Cansu DU, Calisir C, Savas Yavas U, Kasifoglu T, Korkmaz C. Predictors of radiographic severity and functional disability in Turkish patients with ankylosing spondylitis. Clin Rheumatol. 2011;30(4):557-562.

    Not in our library10.1007/s10067-010-1665-2

  69. 69.

    Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955-959.

    Not in our library10.1136/ard.2007.075754

  70. 70.

    Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73.

    Not in our library10.1136/annrheumdis-2013-203582

  71. 71.

    Rubio Vargas R, van den Berg R, van Lunteren M, Ez-Zaitouni Z, Bakker PA, Dagfinrud H, et al. Does body mass index (BMI) influence the ankylosing spondylitis disease activity score in axial spondyloarthritis?: data from the SPACE cohort. RMD Open. 2016;2(1):e000283.

    Not in our library10.1136/rmdopen-2016-000283

  72. 72.

    Jung YO, Kim I, Kim S, Suh CH, Park HJ, Park W, Kwon SR, Jeong JC, Lee YJ, Ryu HJ, Park YB, Lee J, Lee YH, Seo YI, Chung WT, Hong SJ, Hong YS, Baek HJ, Choi HJ, Kang HJ, Lee CH, Kim SH, Kim HA. Clinical and radiographic features of adult-onset ankylosing spondylitis in Korean patients: comparisons between males and females. J Korean Med Sci. 2010;25(4):532-535.

    Not in our library10.3346/jkms.2010.25.4.532

  73. 73.

    Lee W, Reveille JD, Davis JC, Learch TJ, Ward MM, Weisman MH. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis. 2007;66(5):633-638.

    Not in our library10.1136/ard.2006.060293

  74. 74.
    Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study · 2012
    Not checked
  75. 75.

    Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, Veeger NJGM, van Ooijen PMA, Wolf R, Bootsma H, van der Veer E, Arends S. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-alpha blocking therapy: a prospective longitudinal observational cohort study. PLoS One. 2015;10(4):e0122693.

    Not in our library10.1371/journal.pone.0122693

  76. 76.

    Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep. 2011;13(5):383-387.

    Not in our library10.1007/s11926-011-0192-8

  77. 77.

    van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewe R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 2012;71(4):518-523.

    Not in our library10.1136/annrheumdis-2011-200411

  78. 78.

    Jang JH, Ward MM, Rucker AN, Reveille JD, Davis JC Jr, Weisman MH, et al. Ankylosing spondylitis: patterns of radiographic involvement—a re-examination of accepted principles in a cohort of 769 patients. Radiology. 2011;258(1):192–8.

    Not in our library10.1148/radiol.10100426

  79. 79.

    Aggarwal R, Malaviya AN. Clinical characteristics of patients with ankylosing spondylitis in India. Clin Rheumatol. 2009;28(10):1199-1205.

    Not in our library10.1007/s10067-009-1227-7

  80. 80.

    Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717-727.

    Not in our library10.1002/art.24483

  81. 81.

    Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC, Reveille JD, Weisman MH. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum. 2009;61(7):859-866.

    Not in our library10.1002/art.24585

  82. 82.

    Boonen A, vander Cruyssen B, de Vlam K, Steinfeld S, Ribbens C, Lenaerts J, et al. Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol. 2009;36(6):1249-1255.

    Not in our library10.3899/jrheum.080831

  83. 83.

    Calin A, Mackay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol. 1999;26(4):988-992.

    Not in our library

  84. 84.

    Kidd B, Mullee M, Frank A, Cawley M. Disease expression of ankylosing spondylitis in males and females. J Rheumatol. 1988;15(9):1407-1409.

    Not in our library

  85. 85.

    Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landewé R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455-1461.

    Not in our library10.1136/annrheumdis-2014-205178

  86. 86.

    Montilla C, Diaz-Alvarez A, Calero-Paniagua I, Collantes-Estevez E, Font P, Almodovar R, Zarco P, Queiro-Silva R, Canete JD, Juanola X, Mulero J, de Miguel E, Gratacos J, on behalf of the REGISPONSER Study Group. Ankylosing spondylitis without axial progression: analysis of associated factors. J Rheumatol. 2014;41(12):2409-12.

    Not in our library10.3899/jrheum.140018

  87. 87.

    Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556-562.

    Not in our library10.1016/j.semarthrit.2014.10.009

  88. 88.

    Rusman T, Nurmohamed MT, van Denderen JC, Visman I, van der Horst-Bruinsma IE. Female gender is associated with a poorer response to tnf inhibitors in ankylosing spondylitis [abstract]. Ann Rheum Dis. 2017;

    Not in our library

  89. 89.

    Rusman T, ten Wolde S, Euser SM, van der Ploeg T, van Hall O, Van der Horst - Bruinsma IE. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice [in press]. Int J Rheum Dis. 2018 Apr;21(4):836–42 10.1111/1756-185X.13271.

    Not in our library10.1111/1756-185x.13271

  90. 90.

    Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-1155.

    Not in our library10.1136/annrheumdis-2012-201933

  91. 91.

    Gulfe A, Kapetanovic MC, Kristensen LE. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scand J Rheumatol. 2014;43(6):493-497.

    Not in our library10.3109/03009742.2014.918173

  92. 92.

    Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47:343-350.

    Not in our library10.1016/j.semarthrit.2017.04.005

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.